Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XmAb18087 |
| Synonyms | |
| Therapy Description |
XmAb18087 (Tidutamab) is a bispecific monoclonal antibody that targets CD3 and somatostatin receptor 2 (SSTR2), which once bound to tumor cells expressing SSTR2, may elicit an immune response, resulting in cell death (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XmAb18087 | XmAb 18087|XmAb-18087|Tidutamab | CD3 Antibody 119 | XmAb18087 (Tidutamab) is a bispecific monoclonal antibody that targets CD3 and somatostatin receptor 2 (SSTR2), which once bound to tumor cells expressing SSTR2, may elicit an immune response, resulting in cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04590781 | Phase Ib/II | Pembrolizumab + XmAb18087 XmAb18087 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT03411915 | Phase I | XmAb18087 | A Study of XmAb18087 in Subjects With NET and GIST | Completed | USA | 0 |